Diagnostics

The diagnostics firm's new offering combines sample collection with CRO and CDMO services, aiming to slash timelines and reduce regulatory risk for developers.

A breakthrough liquid biopsy shows over 80% accuracy in finding feline lymphoma, offering a non-invasive screening tool for vets and hope for cat owners.

The biotech firm launches an early access program for its novel platform, starting with a tau assay that could revolutionize Alzheimer's research.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

A new partnership brings revolutionary 3D genome mapping from the lab to the clinic, offering new hope for patients with hard-to-treat cancers.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

Replicate Bioscience secures major funding to develop next-gen self-replicating RNA vaccines, aiming for more durable and accessible global health solutions.

AI data platform Protege raises its Series A to $65M, tackling the critical data bottleneck with an ethical, licensing-first model for real-world data.

A newly validated genetic test accurately predicts melanoma risk, offering a non-invasive alternative to the standard surgical biopsy for many patients.

After success in Europe, Allotex gets FDA nod to begin U.S. trials for its tissue-based presbyopia treatment, offering new hope for millions.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Dr. Jesse Ehrenfeld's jump to Aidoc validates enterprise AI's role in medicine, as the tech giant surpasses 100 million patient scans analyzed.

Teal Health's FDA-authorized Teal Wand is now available in all 50 states, aiming to revolutionize preventive care for millions of overdue women.

Health tech firm IMVARIA, maker of an FDA-authorized AI for lung disease, has secured strategic funding from InHealth Ventures and Labcorp to expand its reach.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

A new alliance aims to replace painful biopsies with high-res biology, mapping organ rejection at the cellular level to usher in a new era of personalized care.

New data from a major Swedish study reveals SAGA Diagnostics' Pathlight test can predict colorectal cancer recurrence with remarkable accuracy, changing the game.

A new blood test in Western Canada promises to detect 59 cancers early. But with a high price tag and pending approval, it raises critical questions.

Following record financial growth, RadNet promotes four executives to accelerate its shift toward proactive, AI-driven healthcare and expand its market dominance.